Cost-Effectiveness of First-Line Immunotherapy for Advanced Non-Small Cell Lung Cancer with Different PD-L1 Expression Levels: A Comprehensive Overview.

[1]  P. Nghiem,et al.  Extended duration of treatment using reduced-frequency dosing of anti-PD-1 therapy in patients with advanced melanoma and Merkel cell carcinoma , 2023, Cancer Immunology, Immunotherapy.

[2]  M. Ellen,et al.  Evaluating trends in private equity ownership and impacts on health outcomes, costs, and quality: systematic review , 2023, BMJ.

[3]  A. Desai,et al.  Immunotherapy-based combinations in metastatic NSCLC. , 2023, Cancer treatment reviews.

[4]  T. Bärnighausen,et al.  Estimates and Projections of the Global Economic Cost of 29 Cancers in 204 Countries and Territories From 2020 to 2050 , 2023, JAMA oncology.

[5]  Anubhab Mukherjee,et al.  Lung cancer immunotherapy: progress, pitfalls, and promises , 2023, Molecular Cancer.

[6]  Feng Xie,et al.  Sponsorship bias in oncology cost effectiveness analysis. , 2023, Journal of clinical epidemiology.

[7]  L. Paz-Ares,et al.  At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC , 2023, Nature Reviews Clinical Oncology.

[8]  P. Tian,et al.  Cost-Effectiveness of Pembrolizumab for the treatment of Non–Small-Cell lung cancer: A systematic review , 2022, Frontiers in Oncology.

[9]  Qianchuan Zhao,et al.  Cost-Utility Analysis of Camrelizumab Plus Chemotherapy Versus Chemotherapy Alone as a First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer in China , 2022, Frontiers in Oncology.

[10]  Zhen Zhou,et al.  The Cost-Effectiveness of Tislelizumab Plus Chemotherapy for Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer , 2022, Frontiers in Pharmacology.

[11]  Feng Xie,et al.  Industry sponsorship bias in cost effectiveness analysis: registry based analysis , 2022, BMJ.

[12]  Xiuting Mo,et al.  Cost-Effectiveness of First-Line Nivolumab Plus Ipilimumab Combination Therapy in Advanced Non-Small-Cell Lung Cancer in Japan , 2022, Clinical Drug Investigation.

[13]  J. Penrod,et al.  Cost-effectiveness analysis of nivolumab plus ipilimumab versus platinum-doublet chemotherapy for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States , 2022, Journal of medical economics.

[14]  J. Penrod,et al.  Cost-effectiveness analysis of nivolumab plus ipilimumab plus two cycles of platinum-doublet chemotherapy versus platinum-doublet chemotherapy alone for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States , 2022, Journal of medical economics.

[15]  D. de Ruysscher,et al.  Immunotherapy in unresectable stage III non-small cell lung cancer: state of the art and novel therapeutic approaches. , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  Hongchao Li,et al.  Cost-effectiveness analysis of sintilimab + chemotherapy versus camrelizumab + chemotherapy for the treatment of first-line locally advanced or metastatic nonsquamous NSCLC in China , 2022, Journal of medical economics.

[17]  Xiongwei Xu,et al.  The Predictive Value of PD-L1 Expression Level in Evaluating the Cost-Effectiveness of Atezolizumab/Pembrolizumab , 2022, Frontiers in Oncology.

[18]  Chongqing Tan,et al.  Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50% , 2022, Frontiers in Pharmacology.

[19]  M. Hellmann,et al.  First-Line Immunotherapy for Non-Small-Cell Lung Cancer. , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Chongqing Tan,et al.  First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis , 2021, Frontiers in Pharmacology.

[21]  Jie Zhao,et al.  Economic Evaluation of First-Line Camrelizumab for Advanced Non-small-cell Lung Cancer in China , 2021, Frontiers in Public Health.

[22]  C. Gross,et al.  Cost-Effectiveness of Nivolumab Plus Ipilimumab With and Without Chemotherapy for Advanced Non-Small Cell Lung Cancer , 2021, Frontiers in Oncology.

[23]  Non-small Cell Lung Cancer: Current Therapies and New Targeted Treatments , 2021 .

[24]  Chongqing Tan,et al.  Cost-Effectiveness of Domestic PD-1 Inhibitor Camrelizumab Combined With Chemotherapy in the First-Line Treatment of Advanced Nonsquamous Non–Small-Cell Lung Cancer in China , 2021, Frontiers in Pharmacology.

[25]  X. Liu,et al.  First-line Cemiplimab versus Standard Chemotherapy in Advanced Non-small Cell Lung Cancer Patients with at Least 50% Programmed Cell Death Receptor Ligand-1 Positivity: Analysis of Cost-effectiveness. , 2021, Clinical oncology (Royal College of Radiologists (Great Britain)).

[26]  A. Haslam,et al.  Characteristics of Cost-effectiveness Studies for Oncology Drugs Approved in the United States From 2015-2020 , 2021, JAMA network open.

[27]  T. Farragher,et al.  Factors Limiting Subgroup Analysis in Cost-Effectiveness Analysis and a Call for Transparency , 2021, PharmacoEconomics.

[28]  P. Guyot,et al.  Cost-Effectiveness of Cemiplimab Versus Standard of Care in the United States for First-Line Treatment of Advanced Non-small Cell Lung Cancer With Programmed Death-Ligand 1 Expression ≥50. , 2021, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[29]  T. Kongnakorn,et al.  Modeling Challenges in Cost-Effectiveness Analysis of First-Line Immuno-Oncology Therapies in Non-small Cell Lung Cancer: A Systematic Literature Review , 2021, PharmacoEconomics.

[30]  Shao Liu,et al.  Atezolizumab compared to chemotherapy for first-line treatment in non-small cell lung cancer with high PD-L1 expression: a cost-effectiveness analysis from US and Chinese perspectives , 2021, Annals of translational medicine.

[31]  Qijian Deng,et al.  Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer , 2021, Frontiers in Pharmacology.

[32]  Yalin Dong,et al.  Determining the optimal PD‐1/PD‐L1 inhibitors for the first‐line treatment of non‐small‐cell lung cancer with high‐level PD‐L1 expression in China , 2021, Cancer medicine.

[33]  C. Boshoff,et al.  Toward personalized treatment approaches for non-small-cell lung cancer , 2021, Nature Medicine.

[34]  Chongqing Tan,et al.  Cost-Effectiveness Analysis of Cemiplimab Versus Chemotherapy as First-Line Treatment in Advanced NSCLC with PD-L1 Expression Levels of at Least 50% , 2021, Advances in Therapy.

[35]  X. Hao,et al.  Cost-Effectiveness of Nivolumab Plus Ipilimumab as First-Line Therapy in Advanced Non–small-cell Lung Cancer , 2021, Frontiers in Pharmacology.

[36]  Chongqing Tan,et al.  Cost-Effectiveness of Nivolumab Plus Ipilimumab Combined with Two Cycles of Chemotherapy as First-Line Treatment in Advanced Non-Small Cell Lung Cancer , 2021, Advances in Therapy.

[37]  James D. Murphy,et al.  Cost-effectiveness of Nivolumab-Ipilimumab Combination Therapy for the Treatment of Advanced Non–Small Cell Lung Cancer , 2021, JAMA network open.

[38]  Guoqiang Liu,et al.  Cost-Effectiveness Analysis of Atezolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer With Different PD-L1 Expression Status , 2021, Frontiers in Oncology.

[39]  P. Queirolo,et al.  Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review , 2021, BMC cancer.

[40]  Chongqing Tan,et al.  First-Line Atezolizumab for Metastatic NSCLC with High PD-L1 Expression: A United States-Based Cost-Effectiveness Analysis , 2021, Advances in Therapy.

[41]  C. Panje,et al.  A cost-effectiveness analysis of pembrolizumab with or without chemotherapy for the treatment of patients with metastatic, non-squamous non-small cell lung cancer and high PD-L1 expression in Switzerland , 2021, The European Journal of Health Economics.

[42]  Jie Zhao,et al.  First-line atezolizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: a cost-effectiveness analysis from China , 2021, Expert review of pharmacoeconomics & outcomes research.

[43]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[44]  J. Cook,et al.  A Review of Cost-Effectiveness Studies of Pembrolizumab Regimens for the Treatment of Advanced Non-small Cell Lung Cancer , 2021, PharmacoEconomics - Open.

[45]  J. Feliciano,et al.  Cost-effectiveness of pembrolizumab + chemotherapy versus chemotherapy and pembrolizumab monotherapy in first line treatment of NSCLC in the US – updated analyses with additional trial follow-up , 2021, Journal of medical economics.

[46]  Caicun Zhou,et al.  The cutting-edge progress of immune-checkpoint blockade in lung cancer , 2020, Cellular & Molecular Immunology.

[47]  James Lomas,et al.  A Health Opportunity Cost Threshold for Cost-Effectiveness Analysis in the United States , 2020, Annals of Internal Medicine.

[48]  D. Carbone,et al.  Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab vs. Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer , 2020, Frontiers in Oncology.

[49]  Ziqi Ye,et al.  Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: A systematic review , 2020, PloS one.

[50]  Shun Lu,et al.  The effect of PD-L1 categories-directed pembrolizumab plus chemotherapy for newly diagnosed metastatic non-small-cell lung cancer: a cost-effectiveness analysis , 2020, Translational lung cancer research.

[51]  W. Liang,et al.  Cost-effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced NSCLC. , 2020, Immunotherapy.

[52]  W. Padula,et al.  Is the Choice of Cost-Effectiveness Threshold in Cost-Utility Analysis Endogenous to the Resulting Value of Technology? A Systematic Review , 2020, Applied Health Economics and Health Policy.

[53]  Yuan Jiang,et al.  Cost-effectiveness analysis of pembrolizumab plus standard chemotherapy versus chemotherapy alone for first-line treatment of metastatic non-squamous non–small-cell lung cancer in China , 2020, European journal of hospital pharmacy : science and practice.

[54]  C. Robert,et al.  Immunotherapy discontinuation — how, and when? Data from melanoma as a paradigm , 2020, Nature Reviews Clinical Oncology.

[55]  Pinfang Huang,et al.  Cost-effectiveness of atezolizumab plus chemotherapy for advanced non-small-cell lung cancer , 2020, International Journal of Clinical Pharmacy.

[56]  Maobai Liu,et al.  Economic Evaluations of Immune Checkpoint Inhibitors for Patients with Non-Small Cell Lung Cancer: A Systematic Review , 2020, Cancer management and research.

[57]  C. Toh,et al.  Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer , 2020, Journal of medical economics.

[58]  Xiongwei Xu,et al.  Cost–Utility Analysis of Pembrolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer With Different PD-L1 Expression Levels , 2020, Oncology research.

[59]  Jin Huang,et al.  Cost-Effectiveness Analysis of Atezolizumab Plus Chemotherapy in the First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer , 2020, Advances in Therapy.

[60]  C. Kong,et al.  Cost-effectiveness of pembrolizumab for advanced non-small cell lung cancer patients with varying comorbidity burden , 2020, PloS one.

[61]  Tian-tian Zhang,et al.  Cost‐effectiveness analysis of pembrolizumab plus chemotherapy with PD‐L1 test for the first‐line treatment of NSCLC , 2020, Cancer medicine.

[62]  Arjun Bhadhuri,et al.  Cost effectiveness of pembrolizumab vs chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in Switzerland. , 2019, Swiss medical weekly.

[63]  Chongqing Tan,et al.  Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA , 2019, BMJ Open.

[64]  J. Feliciano,et al.  Cost-effectiveness of pembrolizumab versus chemotherapy as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in USA. , 2019, Immunotherapy.

[65]  D. Carbone,et al.  Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater. , 2019, Lung cancer.

[66]  Chongqing Tan,et al.  First‐line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non–small cell lung cancer: A United States–based cost‐effectiveness analysis , 2019, Cancer.

[67]  Qiu Li,et al.  Cost-effectiveness analysis of pembrolizumab monotherapy and chemotherapy in the non-small-cell lung cancer with different PD-L1 tumor proportion scores. , 2019, Lung cancer.

[68]  S. Chandwani,et al.  Cost Effectiveness of PD-L1-Based Test-and-Treat Strategy with Pembrolizumab as the First-Line Treatment for Metastatic NSCLC in Hong Kong , 2019, PharmacoEconomics - Open.

[69]  C. Kong,et al.  Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non–Small Cell Lung Cancer in the United States , 2019, JAMA network open.

[70]  S. Khozin,et al.  Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[71]  D. Hutton,et al.  Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China , 2019, Journal of medical economics.

[72]  A. Millier,et al.  Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France. , 2019, Lung cancer.

[73]  A. Jemal,et al.  Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[74]  Joe Y. Chang,et al.  A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors , 2018, Journal of Immunotherapy for Cancer.

[75]  P. Aguiar,et al.  Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small cell lung cancer. , 2018, Lung cancer.

[76]  J. Hay,et al.  First-line pembrolizumab in PD-L1 positive non-small-cell lung cancer: A cost-effectiveness analysis from the UK health care perspective. , 2018, Lung cancer.

[77]  Andrea Cipriani,et al.  How to carry out a literature search for a systematic review: A practical guide , 2018 .

[78]  Praveen Thokala,et al.  Cost-Effectiveness Thresholds: the Past, the Present and the Future , 2018, PharmacoEconomics.

[79]  V. Velcheti,et al.  Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States , 2017, PharmacoEconomics.

[80]  M. Mehta,et al.  A systematic review of the cost and cost‐effectiveness studies of proton radiotherapy , 2016, Cancer.

[81]  M. Friedberg,et al.  Associations Between Industry Sponsorship and Results of Cost-effectiveness Analyses of Drugs Used in Breast Cancer Treatment. , 2016, JAMA oncology.

[82]  P. Jänne,et al.  Delay of treatment change after objective progression on first‐line erlotinib in epidermal growth factor receptor‐mutant lung cancer , 2015, Cancer.

[83]  Sydney Rosen,et al.  Thresholds for the cost–effectiveness of interventions: alternative approaches , 2014, Bulletin of the World Health Organization.

[84]  R. Golub,et al.  Meta-analysis as evidence: building a better pyramid. , 2014, JAMA.

[85]  Kwok-Kin Wong,et al.  Non-small-cell lung cancers: a heterogeneous set of diseases , 2014, Nature Reviews Cancer.

[86]  Y. Chae,et al.  Financial Conflicts of Interest in Economic Analyses in Oncology , 2010, American journal of clinical oncology.

[87]  T. Haddad,et al.  Conflict of interest in economic analyses of aromatase inhibitors in breast cancer: a systematic review , 2010, Breast Cancer Research and Treatment.

[88]  A. Adjei,et al.  Small cell lung cancer. , 2008, Mayo Clinic proceedings.

[89]  S. Knoth,et al.  Industry-sponsored economic studies in oncology vs studies sponsored by nonprofit organisations , 2003, British Journal of Cancer.

[90]  J. Hay,et al.  Examining the Value and Quality of Health Economic Analyses: Implications of Utilizing the QHES , 2003, Journal of managed care pharmacy : JMCP.

[91]  Sean D Sullivan,et al.  Development and Validation of a Grading System for the Quality of Cost-Effectiveness Studies , 2003, Medical care.

[92]  Howard L. Bleich,et al.  Technical Milestone: Medical Subject Headings Used to Search the Biomedical Literature , 2001, J. Am. Medical Informatics Assoc..

[93]  M. Friedberg,et al.  Evaluation of conflict of interest in economic analyses of new drugs used in oncology. , 1999, JAMA.

[94]  Mark Sculpher,et al.  Subgroups and Heterogeneity in Cost-Effectiveness Analysis , 2012, PharmacoEconomics.

[95]  Anuja Roy,et al.  Medication compliance and persistence: terminology and definitions. , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.